ClinicalTrials.Veeva

Menu
S

Strathfield Retina Clinic | Strathfield, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
Triamcinolone Acetonide
APL-2
KHK4951
Aflibercept
JNJ-81201887
Pegcetacoplan
Ranibizumab
ANX007
MK-8748

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 25 total trials
Locations recently updated

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-87...

Enrolling
Macular Edema
Diabetic Retinopathy
Drug: MK-8748
Drug: Aflibercept

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ...

Enrolling
Macular Degeneration
Geographic Atrophy
Other: Sham Procedure
Drug: JNJ-81201887

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling
Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Drug: Placebo
Drug: Pozelimab

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of int...

Active, not recruiting
Neovascular Age-related Macular Degeneration (nAMD)
Drug: Faricimab

This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degenerati...

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Active, not recruiting
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.

Active, not recruiting
Diabetic Macular Edema
Drug: Faricimab

Trial sponsors

Roche logo
A
C
Janssen (J&J Innovative Medicine) logo
Kyowa Kirin logo
4
A
Bayer logo
Ionis Pharmaceuticals logo
McMaster University logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems